Anti-alpha 1 Antitrypsin antibody (HRP) (ab191350)

Goat polyclonal alpha 1 Antitrypsin antibody conjugated to HRP. Validated in WB, ELISA, IHC, IM, Dot, ICC/IF and tested in Human. Cited in 5 publication(s).

Overview

  • Product name

    Anti-alpha 1 Antitrypsin antibody (HRP)
    See all alpha 1 Antitrypsin primary antibodies
  • Description

    Goat polyclonal to alpha 1 Antitrypsin (HRP)
  • Host species

    Goat
  • Conjugation

    HRP
  • Tested applications

    Suitable for: ICC/IF, WB, ELISA, IHC-Fr, Immunomicroscopy, Dot blotmore details
  • Species reactivity

    Reacts with: Human
  • Positive control

    • WB: Human plasma. ICC/IF: MCF7 cells.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage buffer

    pH: 7.60
    Preservative: 0.01% Gentamicin sulphate
    Constituents: 0.88% Sodium chloride, 1% BSA, 0.42% Potassium phosphate
  • Concentration information loading...
  • Purity

    IgG fraction
  • Purification notes

    This product is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against buffer.
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab191350 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 10 µg/ml.
WB Use at an assay dependent concentration. Detects a band of approximately 55 kDa (predicted molecular weight: 47 kDa).
ELISA Use at an assay dependent concentration.
IHC-Fr Use at an assay dependent concentration.
Immunomicroscopy Use at an assay dependent concentration.
Dot blot Use at an assay dependent concentration.

Target

  • Function

    Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.
    Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).
  • Tissue specificity

    Ubiquitous. Expressed in leukocytes and plasma.
  • Involvement in disease

    Alpha-1-antitrypsin deficiency
  • Sequence similarities

    Belongs to the serpin family.
  • Domain

    The reactive center loop (RCL) extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site within the RCL, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.
  • Post-translational
    modifications

    N-glycosylated. Differential glycosylation produces a number of isoforms. N-linked glycan at Asn-107 is alternatively di-antennary, tri-antennary or tetra-antennary. The glycan at Asn-70 is di-antennary with trace amounts of tri-antennary. Glycan at Asn-271 is exclusively di-antennary. Structure of glycans at Asn-70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc. Some antennae are fucosylated, which forms a Lewis-X determinant.
    Proteolytic processing may yield the truncated form that ranges from Asp-30 to Lys-418.
  • Cellular localization

    Secreted. Endoplasmic reticulum. The S and Z allele are not secreted effectively and accumulate intracellularly in the endoplasmic reticulum and Secreted, extracellular space, extracellular matrix.
  • Information by UniProt
  • Database links

  • Alternative names

    • A1A antibody
    • A1AT antibody
    • A1AT_HUMAN antibody
    • AAT antibody
    • Alpha 1 antiproteinase antibody
    • Alpha 1 antitrypsin antibody
    • Alpha 1 antitrypsin null antibody
    • Alpha 1 protease inhibitor antibody
    • Alpha-1 protease inhibitor antibody
    • Alpha-1-antiproteinase antibody
    • alpha1 proteinase inhibitor antibody
    • Alpha1AT antibody
    • Dom1 antibody
    • PI antibody
    • PI1 antibody
    • PRO0684 antibody
    • PRO2275 antibody
    • Serine (or cysteine) proteinase inhibitor clade A member 1 antibody
    • Serine protease inhibitor 1-1 antibody
    • Serine protease inhibitor A1a antibody
    • Serpin A1 antibody
    • Serpin A1a antibody
    • Serpin peptidase inhibitor clade A member 1 antibody
    • Serpina1 antibody
    • Short peptide from AAT antibody
    • SPAAT antibody
    • Spi1-1 antibody
    see all

Images

  • Anti-alpha 1 Antitrypsin antibody (HRP) (ab191350) at 1/5000 dilution + Human Plasma Total Protein at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 47 kDa
    Observed band size: 55 kDa
    why is the actual band size different from the predicted?


    Exposure time: 20 seconds


    Alpha I Antitrypsin contains three potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.

  • ICC/IF image of ab191350 stained MCF7 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab191350, 10µg/ml) overnight at +4°C. The secondary antibody (green) was ab96931, DyLight® 488 donkey anti-goat IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References

This product has been referenced in:

  • Borel F  et al. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of a-1 Antitrypsin Deficiency. Mol Ther 25:2477-2489 (2017). Read more (PubMed: 29032169) »
  • Li C  et al. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A 108:14258-63 (2011). Read more (PubMed: 21844342) »
See all 6 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab191350.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up